Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jiangsu Kanion Pharmaceutical Co's enterprise value is ¥5,163 Mil.
Jiangsu Kanion Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥366 Mil. Therefore, Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA for today is 14.10.
The historical rank and industry rank for Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600557'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.47 Med: 17.19 Max: 36.39
Current: 14.1
During the past 13 years, the highest EV-to-EBITDA of Jiangsu Kanion Pharmaceutical Co was 36.39. The lowest was 11.47. And the median was 17.19.
SHSE:600557's EV-to-EBITDA is ranked worse than 52.61% of 728
companies
in the Drug Manufacturers industry
Industry Median: 13.23
vs SHSE:600557: 14.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Kanion Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Kanion Pharmaceutical Co's share price for today is ¥12.23.
Jiangsu Kanion Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Kanion Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA falls into.
Jiangsu Kanion Pharmaceutical Co's current Enterprise Value is ¥5,163 Mil.
Jiangsu Kanion Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥366 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) has a EV-to-EBITDA of 14.10 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Kanion Pharmaceutical Co. This is 18% below median its historical median of 17.19. Over the past decade, Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA has ranged from 11.47 to 36.39. According to the industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #383 out of 728 companies in the Drug Manufacturers industry, placing it in the top 52.6%.
Is Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA too high?
Jiangsu Kanion Pharmaceutical Co's current EV-to-EBITDA of 14.10 is 18% below median its 10-year median of 17.19. Over the past 10 years, this metric has ranged from a low of 11.47 to a high of 36.39. The Drug Manufacturers industry median EV-to-EBITDA is 13.23. Jiangsu Kanion Pharmaceutical Co's value of 14.10 is 6.6% above this industry median. Based on the distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #383 out of 728 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangsu Kanion Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Kanion Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #383 out of 728 companies for EV-to-EBITDA. This places Jiangsu Kanion Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.23. Jiangsu Kanion Pharmaceutical Co's value of 14.10 is 6.6% above this benchmark. Historically, Jiangsu Kanion Pharmaceutical Co's own EV-to-EBITDA has ranged from 11.47 to 36.39 over the past decade. While the company's 10-year median is 17.19 vs. the industry median of 13.23, Jiangsu Kanion Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.23, based on 728 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Kanion Pharmaceutical Co's current EV-to-EBITDA of 14.10 is 6.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Kanion Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Kanion Pharmaceutical Co's current EV-to-EBITDA is 14.10, which is 18% below median its own 10-year median of 17.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Kanion Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co (SHSE:600557) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.35, compared to a current price of ¥12.23 — trading 8.4% below its estimated fair value. The current EV-to-EBITDA is 14.10, which is 18% below median its 10-year median of 17.19 and 6.6% above the Drug Manufacturers industry median of 13.23. Jiangsu Kanion Pharmaceutical Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jiangsu Kanion Pharmaceutical Co (SHSE:600557), the current EV-to-EBITDA is 14.10 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Kanion Pharmaceutical Co (SHSE:600557) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥12.23 is trading 8.4% below its estimated GF Value™ of ¥13.35.
GuruFocus considers Jiangsu Kanion Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600557:
EV-to-EBITDA: 14.10 (18% below median its 10-year median of 17.19)
GF Value™: ¥13.35 vs. price of ¥12.23 (8.4% below fair value)
Industry Position: 6.6% above the Drug Manufacturers median (#383 of 728)
No single metric tells the full story. See the SHSE:600557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
87GF Score
Get the complete analysis for SHSE:600557
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600557 has been successfully added to your 
